

Supplemental Materials

Supplemental Table 1. Details for the studies included in this meta-analysis

| | Diagnostic Assay | In/Out patient | Wk1 OP* | Wk2 OP | Wk3 OP | Total | Wk1 NP | Wk2 NP | Wk3 NP | Total | Wk1 SP | Wk2 SP | Wk3 SP | Total |
|------------------------------------|--------------------|----------------|---------|--------|--------|---------|---------|---------|--------|---------|--------|--------|---------|---------|
| Kujawski et al (2020) ¹ | RT-PCR | In & Out | 13/18 | 15/38 | 9/63 | 37/120 | 13/19 | 21/38 | 11/64 | 48/121 | 5/5 | 7/9 | 3/6 | 15/20 |
| Kim et al (2020) ² | RT-PCR (E) | In | .. | .. | .. | .. | 30/31 | 19/30 | 2/11 | 51/72 | 25/26 | 15/26 | 1/9 | 41/61 |
| Lin et al (2020) ³ | RT-PCR (ORF1ab, N) | In | .. | .. | .. | 23/44 | .. | .. | .. | .. | .. | .. | .. | 40/44 |
| Yu et al (2020) ⁴ | RT-PCR (ORF1ab, N) | In | .. | .. | .. | 62/96 | .. | .. | .. | 14/55 | .. | .. | .. | 86/116 |
| Wang et al (2020) ⁵ | RT-PCR (ORF1ab) | In | .. | .. | .. | 126/398 | .. | .. | .. | 5/8 | .. | .. | .. | 72/104 |
| Yang et al (2020) ⁶ | RT-PCR | In & Out | 58/95 | 26/63 | 15/47 | 99/205 | 158/219 | 130/226 | 23/45 | 311/490 | 45/54 | 47/61 | 14/25 | 106/140 |
| Chan et al (2020) ⁷ | RT-PCR (S) | .. | .. | .. | .. | 2/5 | .. | .. | .. | 4/5 | .. | .. | .. | 2/5 |
| Chen et al (2020) ⁸ | RT-PCR(E) | In | 37/44 | 17/57 | 11/93 | 65/194 | .. | .. | .. | .. | 15/15 | 28/38 | 124/194 | 167/247 |
| Lo et al (2020) ⁹ | RT-PCR (ORF1ab, N) | In | .. | .. | .. | .. | 28/36 | 17/24 | 9/16 | 57/84 | 1/1 | 0/0 | 0/0 | 1/1 |
| Wu et al (2020) ¹⁰ | RT-PCR | In | .. | .. | .. | .. | .. | .. | .. | 180/472 | .. | .. | .. | 148/304 |
| Pan et al (2020) ¹¹ | RT-PCR (N) | In | 8/9 | 2/12 | 0/1 | 10/22 | .. | .. | .. | .. | 6/7 | 4/10 | 0/1 | 10/18 |


*Week 1 (Wk1), week 2 (Wk2) and week 3(Wk3) are 0-7, 8-14 and >14 days after symptoms onset, retrospectively. Virus detection in oropharyngeal (OP), nasopharyngeal (NP) and sputum (SP) samples.

Supplemental Table 2. Participant inclusion criteria for each study


| SARS-CoV-2 inclusion criteria for included participants | |
|---|---|
| Kujawski et al (2020) ¹ | Positive RT-PCR in NP swab or OP swab or sputum |
| Kim et al (2020) ² | Positive RT-PCR in NP swab or OP swab |
| Lin et al (2020) ³ | Positive RT-PCR in both OP swab and sputum specimen |
| Yu et al (2020) ⁴ | Positive RT-PCR in NP swab or OP swab or sputum |
| Wang et al (2020) ⁵ | Positive RT-PCR from an unspecified site |
| Yang et al (2020) ⁶ | Confirmed per "Chinese CDC guideline" |
| Chan et al (2020) ⁷ | Positive RT-PCR from NP swab or OP swab or serum |
| Chen et al (2020) ⁸ | At least two RT-PCR positive OP swabs |
| Lo et al (2020) ⁹ | Positive RT-PCR in NP swab or sputum |
| Wu et al (2020) ¹⁰ | Positive RT-PCR in NP swab |
| Pan et al (2020) ¹¹ | Positive RT-PCR in OP swab or sputum |

NP, nasopharyngeal; OP, oropharyngeal


a




b



c




d




Supplemental Figure 1. Rates of SARS-CoV-2 detection by three methods of sampling excluding preprints. Forest plots of detection rates for oropharyngeal swabs (a), nasopharyngeal swabs (b), and sputum (c), and in a pooled analysis (d). The error bars in (d) are 95% confidence intervals (95% CIs). P-values were calculated by the Z-test.


a




b



c




d




Supplemental Figure 2. Rates of SARS-CoV-2 detection by three methods of sampling in three time points (0-7, 8-14 and >14 days post symptom onset. The pre-print study was removed for this analysis. Forest plots of detection rates for oropharyngeal swabs (a), nasopharyngeal swabs (b), and sputum (c). The three sites of sampling were compared with each other based on three time points post symptom onset (d). The error bars in figure 1 d are 95% Confidence Interval (95% CI). P-values were calculated by the Z-test.

a

Oropharyngeal Swab versus Sputum




b




c

Nasopharyngeal Swab versus Sputum



d



Supplemental Figure 3. Rates of SARS-CoV-2 detection restricted to studies with sputum sampling. Sputum results are compared to oropharyngeal swabs (a, b) and nasopharyngeal swabs (c, d). The error bars in (b, d) are 95% confidence intervals (95% CIs). P-values were calculated by the Z-test. NS, non-significant.

References

1. Team C-I. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nat Med* 2020.
2. Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci* 2020; **35**(13): e142.
3. Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19). *Clin Chem Lab Med* 2020.
4. Yu F, Yan L, Wang N, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. *Clin Infect Dis* 2020.
5. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *Jama* 2020.
6. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. *medRxiv* 2020: 2020.02.11.20021493.
7. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; **395**(10223): 514-23.
8. Chen C, Gao G, Xu Y, et al. SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19. *Ann Intern Med* 2020.
9. Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. *Int J Biol Sci* 2020; **16**(10): 1698-707.
10. Wu J, Liu J, Li S, et al. Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. *Travel Med Infect Dis* 2020; 101673.
11. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis* 2020; **20**(4): 411-2.